Pharmaceutical Manufacturing in Japan

Astellas Pharma

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page:

10001+ staff

Recordati Rare Diseases

At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. Social Media Guidelines:

201 to 500 staff

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical Co, Ltd, headquartered in Tokyo, is a research-based pharmaceutical company with world-class drug discovery capabilities, including proprietary antibody engineering technologies. Chugai is committed to creating innovative pharmaceutical products that may satisfy unmet medical needs. Chugai is listed on the Prime Market of the Tokyo Stock Exchange. While maintaining autonomy and management independence, Chugai is an important member of the Roche Group. Additional information is available at Read our Social Media Policy:

5001 to 10000 staff

Shionogi & Co., Ltd

Philosophy The purpose of the Shionogi Group's corporate activities is, as expressed in the opening of its Company Policy, to "supply the best possible medicine to protect the health and wellbeing of the patients we serve." This eternal and unwavering corporate philosophy is a statement of our vision and value to society. To achieve and live by the Company Policy, we have formulated Action Guidelines, which all Shionogi employees share and embrace as norms for daily activities. Through activities based on the Company Policy and the Action Guidelines, Shionogi will continue to contribute to patients, physicians and other healthcare providers, shareholders and investors, and furthermore to society as a whole.

1001 to 5000 staff

Synowledge Llc

Synowledge is a global life sciences solutions company providing drug safety, regulatory affairs and relevant IT services to diverse pharmaceutical, biotechnology and medical devices companies. We provide industry thought leadership and competence in technology to innovate, optimize and maintain their drug safety applications, business processes and other critical IT applications. Our significant global presence, expertise and market-leading technologies assure reliable partnerships and high performance solutions to each of our clientele.

501 to 1000 staff

Towa Pharmaceutical

Founded in Osaka in 1951, for over 70 years we have been dedicated to research, develop, manufacture, and distribute generic medicines to fulfill our Ikigai: Contribute to people’s health and generate genuine smiles. Towa is listed on the Tokyo Stock Exchange and is one of Japan’s main leading companies in its sector. In the current super-aged society, we make continuous efforts for stable supplies of generics that can help reduce users’ medical payments and counter increasing social security and medical costs while maintaining the quality of medical services. In addition to promoting stable supply, quality assurance, and information provision about generics, we focus on research and development of innovative initiatives to make our products easier to take and handle. To enter new markets, we also promote the construction of a structure that can provide Towa group’s added-value formulations to patients around the world through our overseas companies.

1001 to 5000 staff

Eisai Co., Ltd

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners.

1001 to 5000 staff

Pht International, Inc

PHT International is a Contract Research, Development and Manufacturing Organization (CRDMO) providing innovative solutions for worldwide pharmaceutical companies. Founded in 1993, PHT builds partnerships with leading brands through a commitment to integrity, solving problems and lasting relationships. Our operations has been frequently inspected by the FDA and customer. PHT has established an excellent safety, quality, and compliance track record in the global life sciences industry. PHT strives to be one of the leading CDMO companies within the next 5 years.

201 to 500 staff

Otsuka Pharmaceutical Co., Ltd

2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan

5001 to 10000 staff

Dishman Carbogen Amcis Ltd

Dishman is a global, dynamic group of companies offering a continuum of services to the pharmaceutical industry. We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services. The Dishman Group continually invests in the pharmaceutical industry, ensuring Dishman’s businesses can provide pharmaceutical customers with high-value, high-quality products and services today and in the future. Our focus is to add value to the global pharmaceutical industry by serving as a reliable partner. Our business is successful only when our customers are successful.

1001 to 5000 staff

Agc Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S, Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. Visit to learn more.

1001 to 5000 staff

Kyowa Kirin Co., Ltd

Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International.

5001 to 10000 staff

Metagen Therapeutics, Inc

Metagen Therapeutics, Inc. is a drug discovery and development company that leverages the power of gut microbiome design cultivated in Metabologenomics, Inc. We are eager for partnerships in pharmaceutical, healthcare, functional food, and academia that envisions creating future businesses with one of the best microbiome scientist teams. For inquiries, please contact contact@metagentx.com

11 to 50 staff

Amgen Astellas Biopharma

201310 201320204149 Amgen has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K.(AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K, has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses

501 to 1000 staff

Aska Pharmaceutical Co., Ltd

ASKA Pharmaceutical Co, Ltd. is a leading company in the field of Thyroid disease by through supplying a variety of medicines. Furthermore, we utilize our hormonal technology, aim to contribute all patients for obstetrics and gynecology area.

501 to 1000 staff

Otsuka Holdings Co., Ltd

In keeping with the corporate philosophy “Otsuka-people creating new products for better health worldwide” and the Otsuka values of Ryukan-godo (by sweat we recognize the way), Jissho (actualization) and Sozosei (creativity), we strive to do what only Otsuka can do. The Otsuka group supports the lives of people worldwide through a wide range of innovative and creative products including pharmaceuticals, functional beverages, and functional foods. “Otsuka-people creating new products for better health worldwide”3

51 to 200 staff

Spera Pharma, Inc

SPERA PHARMA (SPERA) was spun out from Takeda Pharmaceuticals and became a wholly owned subsidiary of Bushu Pharmaceuticals on July 1, 2017 in Osaka, Japan. On March 2, 2020, Iwaki & Co, Ltd acquired SPERA from Bushu. The IWAKI Group transitioned to a holding company structure under the new name “Astena Group” on June 1, 2021. SPERA has about 250 employees including researchers and technical specialists in the areas of process chemistry, formulation, and analysis, whose prior work with Takeda gave them broad exposure to all aspects of pharmaceutical R&D, manufacturing, and life cycle management across myriad pharmaceutical products and therapeutic areas. They are engaged in contract R&D and manufacturing of pharmaceuticals for the pharmaceutical and biotech industry. SPERA provides a wide offering of services as a CDMO to meet its customers’ needs across the CMC spectrum, including API and Drug Product process development and cGMP manufacturing, analytical method development, technology transfer, and regulatory filings. SPERA works with its clients on pharmaceutical technology as well as R&D strategy from early stages of drug development through to new drug application and launch. With the acquisition of Jitsubo Co, Ltd in April of 2021, SPERA PHARMA can now also offer Jitsubo’s unique liquid phase peptide manufacturing technology, Molecular Hiving™, to its clients. SPERA’s CMC capabilities therapeutic area agnostic; however, most the company’s current clients are focused on oncology, immuno-oncology, CNS, immunology, and rare diseases. The company believes that their expertise in these areas enables them to deliver molecules more rapidly to their partners. SPERA intends to continually expand its efforts into other therapeutic areas with high unmet needs.

201 to 500 staff

Naris Cosmetics

Naris Cosmetics is a pharmaceuticals company based out of 34 Hopper Ave, Nutley, New Jersey, United States.

11 to 50 staff

Nihon Medi-Physics Co., Ltd

We contribute to solving difficult healthcare issues using molecular imaging technologies Nihon Medi-Physics has been contributing to society through useful healthcare products that utilize the unique features of radioisotopes. Based on our mission of ensuring a stable supply of high quality products as well as continuing to develop new products and technologies that meet medical needs, our ultimate goal is to be a company that is always trusted by our stakeholders. Advances in medical technologies have acted as a constant driver for changes in the healthcare environment. Our core business consists of the nuclear medicine scan known as SPECT and PET, which are molecular imaging procedures. Molecular imaging captures and visualizes slight changes that occur inside the body, thus demonstrating extensive potential for challenging medical issues. In particular, a PET scan is an essential tool for the latest cancer treatments. Nihon Medi-Physics obtained approval for the first radiopharmaceutical agent for the PET procedure in Japan in 2005, and ever since, we have been distributing this agent to medical institutions nationwide. In 2015, we opened a tenth PET agent manufacturing site to further strengthen the product distribution network to ensure a stable supply. Moreover, by leveraging the experience and know-how cultivated in the manufacturing and distribution of radiopharmaceuticals, we recently diversified into contract businesses to promote the PET imaging procedure as a drug development tool in both non-clinical and clinical stages. Also, as an R&D oriented pharmaceutical company, we are actively engaged in the development of new products and expansion of our product line. Fully utilizing our strengths with all our effort, we will continue to explore more possibilities to help as many patients as possible achieve better outcomes, for themselves and their loved ones.

501 to 1000 staff

Orphanpacific Inc

OrphanPacific, Inc. is a Japanese pharmaceutical company specializing in the development, manufacturing and distribution of Orphan Drugs. Our mission is to "bring smiles and happiness to patients with rare diseases and their families," and we are committed to tackling the various challenges surrounding rare diseases. By collaborating with pharmaceutical companies and research institutions both domestically and internationally, we strive to deliver new treatments to patients in Japan while also ensuring the stable supply of existing orphan drugs. Our product portfolio focuses on treatments for rare diseases and includes a diverse range of pharmaceuticals aimed at improving patients' quality of life. Our efforts extend to particularly challenging areas within rare diseases, such as ultra-orphan drugs and treatments for pediatric patients. This commitment is rooted in our corporate philosophy of "Leave No One Behind." As a small company with around 50 employees, we each leverage our expertise while expanding our roles and embracing new challenges. Dedicated to pursuing an ethical and sustainable business model, we emphasize our social responsibility. Through collaboration with healthcare professionals and patient organizations, we engage in awareness and information-sharing activities related to rare diseases, ensuring that our initiatives reflect the voices of patients. OrphanPacific continues to create new value at the forefront of rare disease treatment for the benefit of patients.

51 to 200 staff

Sanwa Kagaku Kenkyusho Co., Ltd

SKK was founded in 1953 as a subsidiary of Suzuken. SKK researches, develops, manufactures, and markets pharmaceuticals.

501 to 1000 staff

A2 Healthcare Corporation

Unlock the potential of global drug development with A2 Healthcare. Expedite your entry into the dynamic healthcare markets of Japan and Taiwan. – Secure New Drug Application (NDA) approval with A2 Healthcare's unmatched regulatory expertise – Strategic clinical study partner for excellence at every stage of clinical development As a leading clinical Contract Research Organization (CRO) with a team of 1,300 experts, our mission is to catalyze your unparalleled success within Japan and Taiwan's pharmaceutical and biotech sectors. To learn more, contact our Boston office today.

1001 to 5000 staff

Anges Mg, Inc

AnGes MG, Inc. is a biopharmaceutical company founded December based on an innovative discovery by researchers of Osaka University. We specialize in R&D and practical application of genetic medicine. At present, we are engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and NFkB decoy which controls various inflammations. We are also making every effort to develop the HVJ Envelope Vector(a new delivery technology for medicines) through our subsidiary, GenomIdea Inc. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL). We are as determined as ever to continue our efforts to satisfy the expectations of patients and families who await new drugs, as well as those of shareholders, investors, and society as a whole.

51 to 200 staff

Bushu Pharmaceuticals Ltd

Japan’s premier contract manufacturing organization. Offering the best in Pharmaceutical Manufacturing & Supply Chain solutions. We produce high-quality pharmaceutical and medical devices with advanced quality control and supply chain management support. With more than 22 years as a contract manufacturer, we are constantly focused on how to improve our ability to deliver quality products to our customers. Based on our successes, we are now proud to have nearly 70 commercial partnerships.

1001 to 5000 staff

Intellim Corporation

English follows Japanese 20058 CRO iQCRO Becoming Asia's Best CRO Since being founded in 2005, we have always pursued the commitment that values hard work, fosters personal growth, promotes diversity, improves working environment, and recognizes the importance of balance between work and life. These factors directly link to the strong bond between our employees and our company, creating a corporate culture that fosters a sense of unity where everyone can grow side by side. As a trusted drug development partner, we provide a total-solution to clinical development ranging from R&D to the various stages of clinical trials. Thanks to highly dedicated people at intellim, we are very proud of our accomplishment as the fastest-growing independent CRO in Japan. We commit to accelerate the client' global studies with our global network including intellim Korea, intellim Malaysia Corporation and iQ Pharma Services Corporation. We are expanding our services to be "the best CRO in Asia from Japan" and the best partner of the clients. We look forward to supporting your business and collaborating with you in the years to come.

201 to 500 staff

Japan Bio Products Co., Ltd

Japan Bio Products was created in 1954 in Tokyo, Japan. We mainly manufacture placental extracts based ethical drugs. Our medicines are used to support liver functions in chronic liver diseases. The various substances contained in placenta (Hepatocyte growth factors, cytokines, amino acids, proteins.) make wonders to speed up the regeneration of a damaged liver and help it recover its functions. Studies have shown that they help reduce greatly hepatic enzymes when the liver is suffering. They also greatly improve skin condition and significantly reduce symptoms of skin conditions like psoriasis, exzema and acne. They brighten the skin and remove impurities and spots, making it much smoother. Last but not least, they are also very efficient to combat climateric disorders in women. From the uniqueness and success of our products, our company started expanding its business, and created placental extracts based cosmetic products and dietary supplements. We have lotions, serums, creams, masks as well as serums made for mesotherapy. Our dietary supplements mimic the effect of the injection. Last but not least, we also produce aesthetic medecine devices, such as ultra thin walled needles that allow smoother injection of thicker products, and less pain for the patients.(FDA approved, and we are the only company in the world able to make these). One of our best seller is the JBP V-LIFT and V-LIFT premium. These are non-invasive lifting PDO threads. The procedure is not painful, fast (around 30 min) and gives outstanding results that last up to 18 months. To complete our line-up, we also have high quality canulas and hyaluronic acid tissue fillers. Our placental extracts based product are the purest and the safest in the world, thanks to our unique extraction technology and our very strict safety protocol. Our medical devices use cutting edge technology and are of unparalleled quality.

51 to 200 staff

Veritas In Silico Inc

Veritas In Silico is unveiling the mysteries of RNA and harnessing the potential of messenger RNA (mRNA) as a drug target. Powered by our proprietary in silico technology, we have established an entirely new system for drug discovery that focuses on finding drugs against structural motifs on mRNA. The discovery of drugs that target mRNA is a promising direction for drug development and a new paradigm for the pharmaceutical industry. It has the potential for application to any disease, including those for which conventional protein-targeted discovery has not yielded effective treatments. Veritas In Silico’s mission is to build a society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future through the realization of mRNA-targeted drugs.

11 to 50 staff

Jouhou Koukai Services Llc

Jouhou Koukai Services LLC and its businesses provide information and intelligence on the Japanese pharmaceutical market in the fields of drugs and medical devices approval, regulatory and pharmaceutical affairs, market access, prices & reimbursement, and industry data.

51 to 200 staff

Kyowa Pharmaceutical Industry Co., Ltd

501 to 1000 staff

Sugi Medical Research Co., Ltd

We offer comprehensive support for all processes from Phase I-IV. Services: Pre-clinical research, development strategy proposals, clinical trial management, monitoring services, data management, statistical analysis, report preparation, medical writing, Japanese regulatory consultation & more. SMR provides total support in the fields of pharmaceuticals, medical devices, cosmetics, quasi-drugs & more. Our group-owned drugstores (with pharmacies) can provide invaluable data in the Japanese market.

51 to 200 staff

Fuji Pharma Co. Ltd

1001 to 5000 staff

Kyorin Pharmaceutical Co., Ltd

11 to 50 staff

Pharmcentre

PharmCentre is a subsidiary of MakroCare that has focus in Life Sciences industry. We have a global reach with offices in USA, Europe, Japan and South Asia.PharmCentre is ISO 9001, and 27001 certified. Our solutions are designed to support brands and products. The scope of PharmCentre portfolio ranges Medical affairs, Pharmacovigilance Call center, Patient compliance, Product complaints, Clinical Trials, and Healthcare marketing management.

51 to 200 staff

Rohto Pharmaceutical Co., Ltd

ROHTO Pharmaceutical Co, Ltd is a multinational company with a history of over 120 years, renowned for its fast-moving consumer goods and OTC drugs. Headquartered in Osaka, Japan, with various domestic and overseas subsidiaries. Although we were initially known for OTC drugs, part of our DNA is to do the unexpected, and for the purpose of people and society’s well-being, we pursue businesses not limited to pharmaceutical operations. Our devotion to meet and exceed customer expectations is the core of Rohto’s business, which has been our main motivator and guidance throughout these years. Recently we announced our comprehensive Management Vision 2030, establishing the core areas we want to strengthen by 2030. With our spirit of "NEVER SAY NEVER" we strive to make every individual and society healthier. To accomplish this, we are seeking people who can support and accelerate the growth of Rohto. The driving force behind Rohto is unquestionably the “people”. A truly diverse workforce is inherently stronger as it is highlighted by people from varying backgrounds with unique experiences, points of view, and knowledge. We believe that this plays an important role in maximizing creativity and accelerating innovation. Our way of working is by embracing the spirit of close cooperation, taking challenges, stir passionate debate and being action oriented. A career at Rohto will help you realize your potential and push yourself to be the better version of you. Are you ready to take part in this journey?

1001 to 5000 staff

Samsung Biologics

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

1001 to 5000 staff

Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs. Learn more:

1001 to 5000 staff

Katsuyama Pharmaceuticals K.K

Katsuyama Pharmaceuticals K.K. has been engaged in integrated production from receiving raw materials to packaging final products. Our production control system utilizes our many years of experience and integrates the manufacturing department, quality assurance department, and production control department. We also provide high-quality services to our customers with a global-level quality control system.

201 to 500 staff

Micron, Inc

Micron Inc, the leading Japanese imaging CRO, was established in 2005 with expertise in the field of molecular imaging. In recent years, the use of medical imaging techniques such as PET, MRI, CT, and SPECT has been increasing in clinical trials. As the first imaging CRO in Japan with the biggest team of imaging experts in Asia, Micron provides full clinical trial/research support including the following- Handle image data in clinical trials for medical drugs/devices - Establish PET sites - Provide total support for clinical research and investigator-initiated clinical trials - Develop imaging-biomarkers - Distribute image analysis software - Provide support for PET tracer manufacturing Evolving day by day, Micron continues to expand business by securing skilled personnel, gathering technical know-how, systematizing operations, and developing new software. In response to the globalization of new drug development, Micron has solidified a foothold as a leading imaging CRO in Japan as well as Asia-Pacific, striving to further contribute to clinical development. Medical Imaging, CRO, In Country Clinical Care-taker Medical Device Manufacturer, SaMD

51 to 200 staff

Nifuji, Inc

At Nifuji, Inc, located in Tokyo we have been serving as a reliable and dedicated partner in the pharmaceutical industry since our establishment. Our main focus revolves around two essential pillars: supporting pharmaceutical imports for doctors within Japan, and efficiently distributing branded Japanese pharmaceuticals to international counterparts. Comprehensive Pharmaceutical Solutions With an expansive network of partners spanning foreign countries, we specialize in sourcing and delivering a wide spectrum of pharmaceutical products, including licensed and unlicensed pharmaceuticals, and medical devices. Our commitment to fast and reliable delivery is rooted in the recognition of its paramount importance, reflecting a core human value that we hold dear. Ensuring Quality and Compliance In line with our dedication to excellence, we work exclusively with certified suppliers who share our commitment to impeccable quality. Regular visits and inspections ensure that our processes align with the stringent regulations outlined by authorities. This meticulous approach allows us to uphold the highest standards and deliver pharmaceutical solutions that meet and exceed expectations. Unrivaled Expertise in Pharmaceutical Sourcing With a wealth of experience in pharmaceutical sourcing, Nifuji, Inc. excels in procuring even the most challenging-to-obtain products. Our agility in responding to your inquiries, researching requirements, and providing swift information about prices, product availability, expiry dates, and proper storage sets us apart as your go-to partner in addressing unmet pharmaceutical needs. Join us in Shaping the Future of Pharmaceutical Distribution As a beacon of trustworthiness and efficiency in the pharmaceutical landscape, Nifuji welcomes you to embark on a journey of seamless collaboration. Together, let's shape the future of pharmaceutical distribution, transcending borders and enriching lives with access to vital medical solutions.

1 to 10 staff

Airex Co.,ltd

AIREX performs the design of a clean room and its layout and the construction of equipment in accordance with each country GMP. Moreover, clean room apparatus, such as a laminar flow, an isolator, RABS, and decontamination equipment, is also manufactured. Our company is continuing growth based on the steadfast status built as a plant engineering company and a manufacturer in Japan.

201 to 500 staff

Croee Inc

Well designed architecture is not only visually beautiful, but also has to be structurally safe and functional. A clinical trial project design is just a design without extensive research and risk calculations taken into account. In CROèe, we strive to create the perfect project plan whatever the conditions or restrictions of the trial. CROèe, as a CRO and also a specialized patients recruitment company, provide support for pharmaceutical companies and other clients to plan an optimized solution for clinical trials.

201 to 500 staff

Cyto-Facto Inc

Services we provide in the field of cell & gene therapy -Contracted manufacturing of commercial products (CMO)-Process development and manufacturing of clinical products (CDMO)-Quality control testing of CGT products for commercial, clinical and research use -Development, sales, and service business of manufacturing management systems -Consultation for regulatory issues

51 to 200 staff

Els Japan Solutions

Eliquent Japan, formerly known as IDEC, is a Japanese regulatory consulting company. We provide comprehensive regulatory services, market assessment service, licensing support service, etc. We are a part of ELIQUENT Life Sciences that creates an unprecedented assembly of global regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex global regulatory landscape. From thought to finish, concept to commerce, and strategy to execution— ELIQUENT Life Sciences is the singular regulatory resource that clients around the world trust. LEARN MORE about our strategic repositioning and integrated service offerings at eliquent.com Recently, we have created GPTs, “Japan Regulatory Insight,” that allow Q&A about newly issued regulatory notifications in Japan regarding the Japanese Phase 1 waiver and orphan drug designation, which have attracted much attention. If you are a ChatGPT Plus subscriber, please click the link below to use the GPTs "Japan Regulatory Insight." https://chat.openai.com/g/g-D5L83iRSi-japan-regulatory-insight If you would like more detailed advice on your project than GPTs's general advice, please get in touch with Eliquent Japan!

11 to 50 staff

Fujimoto Pharmaceutical Corporation

Fujimoto Pharmaceutical Corporation is a pharmaceuticals company based out of Matsubara, Osaka Prefecture, Japan.

1 to 10 staff

Gni Group Ltd

Headquartered in Japan as a global healthcare company and listed on one of the world’s major stock exchanges, we operate drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the US and China.

1 to 10 staff

J-Pharma

From its establishment in 2005, J-Pharma, a clinical stage bio-venture company with a special focus on membrane transporters, has been conducting an array of unique drug developments by Hitoshi Endou, MD, Ph.D, formerly a professor of Kyorin University Faculty of Medicine. Recently J-Pharma has been placing the highest priority on the clinical development of its original inhibitors of L-type amino acid transporter 1 (“LAT1”) for the treatment of advanced cancer patients who failed to benefit from standard chemotherapy.

11 to 50 staff

Medipal Holdings Corporation

11 to 50 staff

Perseus Proteomics Inc

A biopharmaceutical company developing antibody drugs

11 to 50 staff